Drug | No. of patients | Treatment | Control | RR treatment/control (95% CI) | ||
No. of attacks/No. of courses | Ratio | No. of attacks/No. of courses | Ratio | |||
Studies considering number of attacks per therapeutic course | ||||||
Aminocaproic acid19 | 5 | 2/21 | 0.10 | 24/24 | 1.00 | 0.095 (0.025 to 0.356) |
Danazol21 | 9 | 1/46 | 0.02 | 44/47 | 0.94 | 0.023 (0.003 to 0.162) |
Drug | No. of patients | Treatment | Control | RR treatment/control (95% CI) | ||
No. of attacks/No. of months | Ratio | No. of attacks/No. of months | Ratio | |||
Studies considering number of attacks per months | ||||||
Tranexamic acid20 | 12 | 32/94 | 0.34 | 63/57 | 1.11 | 0.308 (0.195 to 0.479) |
Methyltestosterone22 | 4 | 4/46 | 0.09 | 19/12 | 1.61 | 0.054 (0.013 to 0.163) |
C1 inhibitor23 * | 22 | 131/63 | 2.07 | 267/63 | 4.24 | 0.491 (0.395 to 0.607) |
↵* Number of attacks (expressed as attacks per month) was derived from the attack rate (expressed as attacks per 12 weeks) as reported in the study.